Table 1

Summary of SU5416 Pre-Clinical Trials in TRAMP Model of Prostate Cancer

Early intervention trialLate intervention trialRegression trial
CohortABCDEF
TreatmentVehicleSU5416VehicleSU5416VehicleSU5416
Time (wks)10–1610–1616–2216–22
Wet prostate weight (g)0.064 ± 0.0030.089 ± 0.0251.94 ± 0.8191.34 ± 0.6441.09 ± 0.7751.408 ± 0.954
PIN
 Low grade0001/33 (3%)00
 High grade2/15 (13%)004/33 (12%)00
Cancer
 Well differentiated13/15 (87%)18/21 (86%)16/30 (53%)12/33 (36%)6/18 (33%)7/18 (39%)
 Moderately differentiated00005/18 (28%)5/18 (28%)
 Poorly differentiated03/21 (14%)14/30 (47%)16/33 (49%)7/18 (39%)6/18 (33%)
Lymph node metastasis02/6 (33%)6/9 (67%)7/10 (70%)6/6 (100%)6/6 (100%)
IMVD/field4.83 ± 0.846.3 ± 0.8012.49 ± 0.849.75 ± 0.59NDaND
% Proliferation6.00 ± 0.898.45 ± 1.3117.10 ± 0.8416.05 ± 1.69NDND
% Apoptosis5.57 ± 0.866.99 ± 1.0754.66 ± 0.3612.34 ± 2.03bNDND
  • a ND, Not determined.

  • b Significant increase between animals treated with SU5416 and animals treated with vehicle alone (P < 0.001).